TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03976505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reading a table format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reading a table format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
Study: NCT00175071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison of cooking oils
Description: 30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
Study: NCT03976505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reading a textual format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reading a textual format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Description: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Study: NCT02505815

Intervention type: PROCEDURE
Intervention: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Study: NCT00967057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally
Study: NCT03055689

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education for colonoscopy
Description: Standard education for bowel preparation at the time of colonoscopy scheduling
Study: NCT02505815

Intervention type: PROCEDURE
Intervention: Cortisol Level Measurement
Study: NCT01460667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: 0.9% normal saline IV, every 6 hours over 30 hours.
Study: NCT02505815

Intervention type: PROCEDURE
Intervention: Cortisol Level Measurement

Intervention type: PROCEDURE
Intervention: Neurocognitive Testing

Intervention type: PROCEDURE
Intervention: Neurocognitive Testing
Study: NCT04194957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patients that are heterozygous carriers of c.1236G\>A or c.2846A\>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
Study: NCT06211452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM A: Active Comparator Drug
Description: Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43; cyclophosphamide 500 mg/m2/d, days 29, 43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B: Blocks Therapy Drug
Description: Blocks AI Cytarabine 500 mg/m2 as 24 infusion infusion x 4 d; Idarubicin 7 mg/m2 on days 3 and 5; Intrathecal cytarabine on days 0 and 6.~haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5; Intrathecal cytarabine days 6 and 15.
Study: NCT03391076

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Respiratory Panel
Description: An Multi-PCR method which can detect 20 pathogens in 45 minutes.
Study: NCT04355221

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency
Description: Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency
Description: Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency
Description: Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
Study: NCT01937624

Intervention type: DEVICE
Intervention: Diagnostic Ultrasound

Intervention type: RADIATION
Intervention: X-ray imaging
Study: NCT02268136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIII 890 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04616092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEFINJECT
Description: FEFINJECT injection
Study: NCT02451488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 14 days in a dose of 125 µg/m\^2

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: No neo-adjuvant therapy prior to surgical intervention
Study: NCT05247983

Intervention type: PROCEDURE
Intervention: Tension-free repair of inguinal hernia with Undissociate Spermatic cord
Description: patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord
Study: NCT01386892

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT03945123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red ginseng
Description: Red ginseng tablet 120g
Study: NCT01286714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLIP OST
Study: NCT04502472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion
Description: Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
Study: NCT04313816

Intervention type: OTHER
Intervention: questionnaire
Description: no intervention at all apart from filling a brief questionnaire
Study: NCT03807752

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MPH_active
Description: One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MPH_placebo
Description: One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
Study: NCT04044651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 480 mg IV infusions for 30 minutes q4w
Study: NCT03498196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
Study: NCT03939312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant Tablets
Study: NCT06245681

Intervention type: DRUG
Intervention: gender affirming hormone therapy
Description: both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio

Intervention type: DRUG
Intervention: gender affirming hormone therapy
Description: both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
Study: NCT02030249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie diet administered from 0 to 2 months
Description: The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet administered from 0 to 2 months
Description: The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
Study: NCT03976505

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Description: filling a virtual pillbox displayed on the screen as prescribed in the prescription

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Description: filling a virtual pillbox displayed on the screen as prescribed in the prescription

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Description: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Study: NCT02030249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein / Low Glycaemic Index
Description: Please see description of the Arm by the same name.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Protein / High Glycaemic Index
Description: Please see description of the Arm by the same name.
Study: NCT01773798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 15
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
Study: NCT03736811

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyglactin 910 or polydioxanone
Description: Vicryl or PDS II

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyester or polypropylene
Description: Ethibond Excel or prolene
Study: NCT02249208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tc+blue dye
Description: Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tc+SPIO
Description: Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPIO alone
Description: Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
Study: NCT02305290

Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Study: NCT05621590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC 901
Description: MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules filled with stevia sweetened powder
Study: NCT04165005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: decentering
Description: examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: relaxing guided imagery including breathing exercises.
Study: NCT01797315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Study: NCT02181036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family work shop
Description: 2-3 hours per session, one session per week, a total of 6 weeks of family work shop
Study: NCT02119650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo tablets to be administered by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 administered as an intravenous infusion over 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 administered as an intravenous infusion over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
Study: NCT01932203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: 200mg once a day
Study: NCT04497766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium sulfate
Description: MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Description: pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
Study: NCT00585156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
Study: NCT02332512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Study: NCT03949998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Comparison between dry needling and/or manual therapy of the cervical region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Comparison between dry needling and/or manual therapy of the cervical region.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: soft tissue release, cervical traction and/or cervical mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: soft tissue release, cervical traction and/or cervical mobilization
Study: NCT04042038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (psychological treatment)
Description: Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
Study: NCT00179517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1mg
Study: NCT00039026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT03976505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye-tracker
Description: In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eye-tracker
Description: In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye-tracker
Description: In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eye-tracker
Description: In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tests and questionary
Description: Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tests and questionary
Description: Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tests and questionary
Description: Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tests and questionary
Description: Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
Study: NCT00283101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40 (anti-huCD40 mAb)
Description: 1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
Study: NCT00179517

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet